Ranbaxy Laboratories Ltd has sued the US Food and Drug Administration (FDA) for revoking the tentative approvals of Nexium and Valcyte. The FDA has also withdrawn six-month market exclusivity of Valcyte. The USFDA had banned export of drugs manufactured at the plants of Ranbaxy in India to the US. Ranbaxy had paid fines of $500 million in 2013 on seven counts. Sun Pharma is planning to acquire Ranbaxy for $4 billion.
category: FDA Final Approvals